Quantum Biopharma Class B Subordinate Voting Shares
QNTM
17 hedge funds and large institutions have $1.91M invested in Quantum Biopharma Class B Subordinate Voting Shares in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 5 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
67% more call options, than puts
Call options by funds: $812K | Put options by funds: $486K
10% more capital invested
Capital invested by funds: $1.74M → $1.91M (+$176K)
0.01% more ownership
Funds ownership: 0.04% → 0.05% (+0.01%)
11% less funds holding
Funds holding: 19 → 17 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
+$260K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$96.7K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$42.6K |
| 4 |
VF
Virtu Financial
New York
|
+$29.9K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$13.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Penserra Capital Management
Orinda,
California
|
-$51K |
| 2 |
Two Sigma Advisers
New York
|
-$33.8K |
| 3 |
Jane Street
New York
|
-$31K |
| 4 |
SPIA
Steward Partners Investment Advisory
New York
|
-$5.73K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.04K |
QNTM Hedge Fund Activity: Q2 2021 in Review
17 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Quantum Biopharma Class B Subordinate Voting Shares (QNTM) for Q2 2021, worth a combined $1.91M — up 10% from $1.74M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of QNTM and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 6 added.
The largest buyer was IQ EQ Fund Management, adding an estimated $260K. The largest seller was Penserra Capital Management, exiting entirely with an estimated $51K sold.
- 17 institutional investors held Quantum Biopharma Class B Subordinate Voting Shares (QNTM) as of Q2 2021, down from 19 in Q1 2021.
- Funds reported $1.91M of Quantum Biopharma Class B Subordinate Voting Shares stock for Q2 2021, up 10% quarter-over-quarter.
- 3 funds opened new Quantum Biopharma Class B Subordinate Voting Shares positions in Q2 2021 and 5 closed out, a net change of -2 holders.
- The largest Quantum Biopharma Class B Subordinate Voting Shares buyer in Q2 2021 was IQ EQ Fund Management, an estimated $260K added.
- The largest Quantum Biopharma Class B Subordinate Voting Shares seller in Q2 2021 was Penserra Capital Management, an estimated $51K sold.
Based on aggregated 13F filings for Q2 2021.